Regeneron Pharmaceuticals Inc. (REGN) Dips 3.27% for January 08

Equities Staff  |

Among the S&P 500’s biggest fallers on Monday January 08 was Regeneron Pharmaceuticals Inc. (REGN). The stock experienced a 3.27% decline to $372.52 with 1.08 million shares changing hands.

Regeneron Pharmaceuticals Inc. started at an opening price of 384.40 and hit a high of $387.33 and a low of $371.26. Ultimately, the stock took a hit and finished the day at $12.58 per share. Regeneron Pharmaceuticals Inc. trades an average of 831,342 shares a day out of a total 107.44 million shares outstanding. The current moving averages are a 50-day SMA of $389.18 and a 200-day SMA of $435.73. Regeneron Pharmaceuticals Inc. hit a high of $543.55 and a low of $340.09 over the last year.

Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

With its headquarters located in Tarrytown, NY, Regeneron Pharmaceuticals Inc. employs 5,400 people. After today’s trading, the company’s market cap has fallen to $40.02 billionAs for its value, has a P/E ratio of <34.8, a P/S of 9.65, a P/B of 6.61, and a P/FCF of 71.5.

To dig deeper into the fundamentals of Regeneron Pharmaceuticals Inc. and perform your own analysis, visit our Stock Valuation Analysis tool for REGN.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

For all the attention paid to the Dow Jones Industrial Average (DJIA), it’s the S&P 500 that’s relied on by insiders and institutional investors. It represents the industry standard for American large-cap indices.

The Dow is made up of just 30 stocks to the S&P 500’s 500, and it uses an unreliable and outdated price-weighting system where the S&P 500 relies on market cap in weighting its returns. This is why its long-term returns is a much more reliable gauge for the performance of large- and mega-cap stocks over time.

To get more information on Regeneron Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: REGN’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…